Search
Polymyxin B
go.drugbank.com/drugs/DB00781ApprovedInvestigationalVet approvedPolymyxin B is used for infections with gram-negative organisms, but may be neurotoxic and nephrotoxic[A176426,FDA Label]. … It is appropriate for treatment of infections of the urinary tract, meninges, and blood stream, caused by susceptible strains of _Pseudomonas aeruginosa_[FDA Label].
Mixtures: Premier Value Max Strength Antibiotic plus pain relief, OTEK-P EAR DROPSCategories: Antibacterials for Systemic Use, Antiinfectives for Systemic UseExenatide
go.drugbank.com/drugs/DB01276ApprovedInvestigationalBydureon BCise, an auto-injector extended-release formulation, remains available.[L42700] … [L42685,L42690] Bydureon, the brand name product of extended-release exenatide in an injectable suspension, was discontinued in 2021.
Products: BYDUREON 2 mg powder and solvent for prolonged-release suspension for injection, BYDUREON POWDER AND SOLVENT FOR PROLONGED-RELEASE SUSPENSION FOR INJECTION IN PRE-FILLED PEN 2MGInsulin aspart
go.drugbank.com/drugs/DB01306ApprovedInvestigationalInsulin also inhibits hepatic glucose production, enhances protein synthesis, and inhibits lipolysis and proteolysis among many other functions. … Absorption of glucose into cells allows for its transformation into glycogen or fat for storage.
Mixtures: Ryzodeg® FlexTouch® 100 U/ml Solution for InjectionCategories: Insulins and Analogues for Injection, Fast-Acting, Cytochrome P-450 CYP1A2 InducersLetermovir
go.drugbank.com/drugs/DB12070ApprovedInvestigationalLetermovir recieved approval from the FDA on November 8th, 2017 for use in prophylaxis of cytomegalovirus (CMV) infection in allogeneic hematopoietic stem cell transplant patients.
Categories: Antivirals for Systemic Use, Antiinfectives for Systemic UseProducts: PREVYMIS CONCENTRATE FOR SOLUTION FOR INFUSION 20MG/ML, PREVYMIS 240mg/12mL (20mg/mL) concentrate for solution for infusionVedolizumab
go.drugbank.com/drugs/DB09033ApprovedInvestigational[L48216] Vedolizumab was developed by Takeda and approved by the FDA under the brand name ENTYVIO for the maintenance therapy of moderately to severely active Ulcerative Colitis and Crohn’s Disease … however, the selective activity of vedolizumab against α4β7 integrin has been thought to contribute to its more favorable safety profile compared to its predecessor natalizumab, the first integrin receptor
Categories: Integrin Receptor AntagonistProducts: Entyvio 300mg Powder for Concentrate for Solution for Infusion, ENTYVIO POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 300MG/VIALAntihemophilic factor, human recombinant
go.drugbank.com/drugs/DB00025ApprovedInvestigationalHuman recombinant antihemophilic factor (AHF) or Factor VIII, 2332 residues, glycosylated, produced by CHO cells
Mixtures: HAEMATE P, HAEMATE PProducts: ADVATE 250 IU Powder and Solvent for Solution for Injection, ADVATE 500 IU Powder and Solvent for Solution for InjectionArtesunate
go.drugbank.com/drugs/DB09274ApprovedInvestigational[L890] Artesunate was developed out of a need for a more hydrophilic derivative of [artemisinin].[A203948] Artesunate was granted FDA approval on 26 May 2020.[L14099] … Artesunate is indicated for the initial treatment of severe malaria.[L14099] The World Health Organization recommends artesunate as first line treatment for severe malaria.
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesProducts: ARTESUNATE FOR INJECTION, ARTESUN POWDER FOR INJECTION 60 MGEvolocumab
go.drugbank.com/drugs/DB09303ApprovedInvestigationalIt is approved for both homozygous and heterozygous familial cholesterolemia as an adjunct to other first-line therapies. … Evolocumab is a monoclonal antibody designed for the treatment of hyperlipidemia by Amgen.
Categories: Hypolipidemic Agents Indicated for Hyperlipidemia, Non-statin Hypolipidemic Agents Indicated for HyperlipidemiaProducts: REPATHA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 140MG/ML, Repatha Solution for Injection in Pre-filled Syringe 140mg/mL (evolocumab)Enoxaparin
go.drugbank.com/drugs/DB01225ApprovedInvestigationalEnoxaparin is a common low-molecular-weight heparin (LMWH) used in the prevention and management of various thromboembolic disorders. Initially approved by the FDA in 1993, it is administered by a subcutaneous or intravenous injection an...
Products: ./0.6ML FER, ./0.8ML FERPhenindione
go.drugbank.com/drugs/DB00498ApprovedInvestigationalAn indandione that has been used as an anticoagulant. Phenindione has actions similar to warfarin, but it is now rarely employed because of its higher incidence of severe adverse effects.